드러그인포 약품요약정보 - 헤파토팔크점적용정맥주사

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

662100120[E01830021] [보험코드에 따른 약품기본정보 직접조회]
\0 원/5ml/앰플(2007.12.01)(현재약가)
\2,991 원/5ml/앰플(2001.02.01)(변경전약가)
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

5밀리리터 앰플 [제형정보 확인]

포장·유통단위

10A.IV

효능효과

[적응증 별 검색]

다음 질환의 치료보조 : 만성간염, 간경변
[Drugbank 의 성분정보열람]
[Adenosine][Choline][Hydroxocobalamin]

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
[주성분코드:327000BIJ 에 따른 심사지침열람]
성인 1주일에 1~7회, 나트륨 이온이나 칼륨 이온이 없는 5~20% 과당용액(Fructose Levulose)이나 포도당 용액 500ml에 1~3앰플(3앰플을 초과하지 말것)을 희석하여 정맥내 점적주사한다.
연령증상에 따라 적절히 증감한다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

금기

간성혼수 환자
신기능부전 환자
완전 및 부분적 방실계의 폐색 및 급성 심근경색으로 오는 심근중전도부족 상태

신중투여

저혈압성 순환계 질환이 있는 환자

Off-label Usage

[조회]

Related FDA Approved Drug

기준 성분:HYDROXOCOBALAMIN
ALPHAREDISOL (HYDROXOCOBALAMIN)
CYANOKIT (HYDROXOCOBALAMIN)
HYDROXOCOBALAMIN (HYDROXOCOBALAMIN)
HYDROXOMIN (HYDROXOCOBALAMIN)
기준 성분:CYANOCOBALAMIN
BEROCCA PN (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E)
BERUBIGEN (CYANOCOBALAMIN)
BETALIN 12 (CYANOCOBALAMIN)
CALOMIST (CYANOCOBALAMIN)
CERNEVIT-12 (ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A)
COBAVITE (CYANOCOBALAMIN)
CYANOCOBALAMIN (CYANOCOBALAMIN)
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT (CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR)
DEPINAR (CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE)
DICOPAC KIT (CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58)
INFUVITE ADULT (ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K)
INFUVITE PEDIATRIC (ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K)
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) (ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K)
M.V.C. 9+3 (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E)
M.V.I. ADULT (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K)
M.V.I. ADULT (PHARMACY BULK PACKAGE) (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K)
M.V.I. PEDIATRIC (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E)
M.V.I.-12 (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E)
M.V.I.-12 (WITHOUT VITAMIN K) (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E)
M.V.I.-12 LYOPHILIZED (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E)
MVC PLUS (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E)
NASCOBAL (CYANOCOBALAMIN)
REDISOL (CYANOCOBALAMIN)
RUBIVITE (CYANOCOBALAMIN)
RUBRAMIN PC (CYANOCOBALAMIN)
RUBRATOPE-57 (CYANOCOBALAMIN, CO-57)
RUBRATOPE-57 KIT (COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR)
RUBRATOPE-60 (CYANOCOBALAMIN, CO-60)
RUBRATOPE-60 KIT (COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR)
RUVITE (CYANOCOBALAMIN)
VIBISONE (CYANOCOBALAMIN)
VITAPED (ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E)
VI-TWEL (CYANOCOBALAMIN)
기준 성분:CHOLINE OROTATE
기준 성분:ADENOSINE
ADENOCARD (ADENOSINE)
ADENOSCAN (ADENOSINE)
ADENOSINE (ADENOSINE)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
BIT 약효분류	담즙산분비촉진제 & 간보호제 (Cholelitholitics & Hepatic Protectors)
ATC 코드	Liver therapy / A05BA [코드분류상세설명] [ATC코드예측]
복지부분류코드	391 (간장질환용제 )
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	662100120[E01830021] [보험코드에 따른 약품기본정보 직접조회] \0 원/5ml/앰플(2007.12.01)(최신약가) \2,991 원/5ml/앰플(2001.02.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	5밀리리터 앰플 [제형정보 확인]
포장·유통단위	10A.IV
특수관리의약품 부가정보	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Adenosine에 대한 독성정보 : 정보보기 Cyanocobalamin에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Adenosine에 대한 Mechanism_Of_Action 정보 Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. Choline에 대한 Mechanism_Of_Action 정보 Choline is a major part of the polar head group of phosphatidylcholine. Phosphatidylcholine's role in the maintenance of cell membrane integrity is vital to all of the basic biological processes: information flow, intracellular communication and bioenergetics. Inadequate choline intake would negatively affect all these processes. Choline is also a major part of another membrane phospholipid, sphingomyelin, also important for the maintenance of cell structure and function. It is noteworthy and not surprising that choline deficiency in cell culture causes apoptosis or programmed cell death. This appears to be due to abnormalities in cell membrane phosphatidylcholine content and an increase in ceramide, a precursor, as well as a metabolite, of sphingomyelin. Ceramide accumulation, which is caused by choline deficiency, appears to activate Caspase, a type of enzyme that mediates apoptosis. Betaine or trimethylglycine is derived from choline via an oxidation reaction. Betaine is one of the factors that maintains low levels of homocysteine by resynthesizing L-methionine from homocysteine. Elevated homocysteine levels are a significant risk factor for atherosclerosis, as well as other cardiovascular and neurological disorders. Acetylcholine is one of the major neurotransmitters and requires choline for its synthesis. Adequate acetylcholine levels in the brain are believed to be protective against certain types of dementia, including Alzheimer's disease. Cyanocobalamin에 대한 Mechanism_Of_Action 정보 Vitamin B12 is used in the body in two forms: Methylcobalamin and 5-deoxyadenosyl cobalamin. The enzyme methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells. Hydroxocobalamin에 대한 Mechanism_Of_Action 정보 Vitamin B12 exists in four major forms referred to collectively as cobalamins; deoxyadenosylcobalamin, methylcobalamin, hydroxocobalamin, and cyanocobalamin. Two of these, methylcobalamin and 5-deoxyadenosyl cobalamin, are primarily used by the body. Methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells.
Pharmacology	Adenosine에 대한 Pharmacology 정보 Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine is indicated for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine. Choline에 대한 Pharmacology 정보 This compound is needed for good nerve conduction throughout the CNS (central nervous system) as it is a precursor to acetylcholine (ACh). Choline is also needed for gallbladder regulation, liver function and lecithin (a key lipid) formation. Choline also aids in fat and cholesterol metabolism and prevents excessive fat build up in the liver. Choline has been used to mitigate the effects of Parkinsonism and tardive dyskinesia. Choline deficiencies may result in excessive build-up of fat in the liver, high blood pressure, gastric ulcers, kidney and liver dysfunction and stunted growth. Cyanocobalamin에 대한 Pharmacology 정보 Cyanocobalamin (Vitamin B12) is a water-soluble organometallic compound with a trivalent cobalt ion bound inside a corrin ring. It is needed for nerve cells and red blood cells, and to make DNA. Vitamin B12 deficiency is the cause of several forms of anemia. Hydroxocobalamin에 대한 Pharmacology 정보 Hydroxocobalamin is a synthetic, injectable form of Vitamin B12. Hydroxocobalamin is actually a precursor of two cofactors or vitamins (Vitamin B12 and Methylcobalamin) which are involved in various biological systems in man. Vitamin B12 is required for the conversion of methylmalonate to succinate. Deficiency of this enzyme could therefore interfere with the production of lipoprotein in myelin sheath tissue and so give rise to neurological lesions. The second cofactor, Methylcobalamin, is necessary for the conversion of homocysteine to methionine which is essential for the metabolism of folic acid. Deficiency of tetrahydrafolate leads to reduced synthesis of thymidylate resulting in reduced synthesis of DNA which is essential for cell maturation. Vitamin B12 is also concerned in the maintenance of sulphydryl groups in reduced form, deficiency leading to decreased amounts of reduced SH content of erythrocytes and liver cells. Overall, vitamin B12 acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis. It is necessary for growth, cell replication, hematopoiesis, and nucleoprotein as well as myelin synthesis. This is largely due to its effects on metabolism of methionine folic acid, and malonic acid.
Metabolism	Adenosine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Adenosine deaminaseAdenosine kinase Choline에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cholinesterase Cyanocobalamin에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Methylenetetrahydrofolate reductase Hydroxocobalamin에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available
Protein Binding	Cyanocobalamin에 대한 단백결합 정보 Very high (to specific plasma proteins called transcobalamins); binding of hydroxocobalamin is slightly higher than cyanocobalamin. Hydroxocobalamin에 대한 단백결합 정보 Very high (90%). Cobalamins are extensively bound to two specific plasma proteins called transcobalamin 1 and 2; 70% to transcobalamin 1, 5% to transcobalamin 2.
Half-life	Adenosine에 대한 반감기 정보 Less than 10 secs Cyanocobalamin에 대한 반감기 정보 Approximately 6 days (400 days in the liver). Hydroxocobalamin에 대한 반감기 정보 Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)
Absorption	Adenosine에 대한 Absorption 정보 Not Available Choline에 대한 Absorption 정보 Not Available Cyanocobalamin에 대한 Absorption 정보 Readily absorbed in the lower half of the ileum. Hydroxocobalamin에 대한 Absorption 정보 Readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Vitamin B12 is absorbed in the lower half of the ileum.
Pharmacokinetics	Hydroxocobalamin의 약물동력학자료 흡수 : 경구 투여시 소장 원위부로부터 불규칙적으로 흡수된다. 능동 흡수에는 IF와의 복합체 형성이 필수적이며, 장관벽을 통해 수동 흡수도 가능하다. 위, 회장에 구조적 손상이나 기능적 손상이 있는 경우 흡수가 감소한다. 분포 : 위에서 위점막에 의해 분비되는 당단백인 IF (intrinsic factor)에 결합한다. 장관 점막세포 내에서 vitamin B₁₂-IF 복합체로부터 vitamin B₁₂가 유리된 후, 혈액 내에서 주로 특이적인 β-globulin 수송단백질인 transcobalamin II와 결합한다. 간, 골수 및 태반을 포함한 기타 조직으로 분포하며, 주로 간 (50-90%)에 저장된다. 단백결합 : 주로 transcobalamin II와 결합하며, 소량은 transcobalamin I (α-glycoprotein의 일종) 및 transcobalamin III (inter-α-glycoprotein의 일종)과 결합한다. 대사 : 장간순환 소실 : Vitamin B₁₂를 투여받고 있지 않는 정상인 : 많은 양이 담즙 배설 후 장간순환한다. 일일 turnover rate : 체내 총저장량의 0.05-0.2% (범위 : 0.4-8 μg) 일일 신배설량은 대개 0.25 μg 이하 Vitamin B₁₂를 투여받는 경우 : 0.1-1 mg 근육주사 또는 정맥주사 후 48시간 이내에 50-90%가 신배설된다. Adenosine의 약물동력학자료 효과발현시간 : 임상효과는 매우 빠르게 나타남 작용지속시간 : 매우 짧음 대사 : 혈액과 조직에서 inosine으로 대사된 후 adenosine monophosphate (AMP)와 hypoxanthine으로 대사됨 반감기 : 10초이내, 부작용도 대부분 빠르게 사라짐 Cyanocobalamin의 약물동력학자료 흡수 : 경구 투여시 소장 원위부로부터 불규칙적으로 흡수된다. 능동 흡수에는 IF와의 복합체 형성이 필수적이며, 장관벽을 통해 수동 흡수도 가능하다. 위, 회장에 구조적 손상이나 기능적 손상이 있는 경우 흡수가 감소한다. 분포 : 위에서 위점막에 의해 분비되는 당단백인 IF (intrinsic factor)에 결합한다. 장관 점막세포 내에서 vitamin B₁₂-IF 복합체로부터 vitamin B₁₂가 유리된 후, 혈액 내에서 주로 특이적인 β-globulin 수송단백질인 transcobalamin II와 결합한다. 간, 골수 및 태반을 포함한 기타 조직으로 분포하며, 주로 간 (50-90%)에 저장된다. 단백결합 : 주로 transcobalamin II와 결합하며, 소량은 transcobalamin I (α-glycoprotein의 일종) 및 transcobalamin III (inter-α-glycoprotein의 일종)과 결합한다. 대사 : 장간순환 소실 : Vitamin B₁₂를 투여받고 있지 않는 정상인 : 많은 양이 담즙 배설 후 장간순환한다. 일일 turnover rate : 체내 총저장량의 0.05-0.2% (범위 : 0.4-8 μg) 일일 신배설량은 대개 0.25 μg 이하 Vitamin B₁₂를 투여받는 경우 : 0.1-1 mg 근육주사 또는 정맥주사 후 48시간 이내에 50-90%가 신배설된다.
Biotransformation	Adenosine에 대한 Biotransformation 정보 Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Cyanocobalamin에 대한 Biotransformation 정보 Hepatic Hydroxocobalamin에 대한 Biotransformation 정보 Primarily hepatic. Cobalamins are absorbed in the ileum and stored in the liver. They continuously undergo enterohepatic recycling via secretion in the bile. Part of a dose is excreted in the urine, most of it in the first 8 hours.
Toxicity	Adenosine에 대한 Toxicity 정보 Not Available Choline에 대한 Toxicity 정보 Oral rat LD₅₀: 3400 mg/kg Cyanocobalamin에 대한 Toxicity 정보 Anaphylactic reaction (skin rash, itching, wheezing)-after parenteral administration. ORL-MUS LD₅₀ > 8000 mg/kg Hydroxocobalamin에 대한 Toxicity 정보 Not Available
Drug Interactions	Adenosine에 대한 Drug_Interactions 정보 Aminophylline This xanthine decreases the effect of adenosineDipyridamole Dipyridamole increases the effect/toxicity of adenosineDyphylline This xanthine decreases the effect of adenosineTheophylline This xanthine decreases the effect of adenosineDyphylline This xanthine decreases the effect of adenosineOxtriphylline This xanthine decreases the effect of adenosineTheophylline This xanthine decreases the effect of adenosine Choline에 대한 Drug_Interactions 정보 Not Available Cyanocobalamin에 대한 Drug_Interactions 정보 Not Available Hydroxocobalamin에 대한 Drug_Interactions 정보 Alfentanil The macrolide increases the effect and toxicity of alfentanilAlprazolam The macrolide increases the effect of the benzodiazepineAminophylline The macrolide increases the effect and toxicity of theophyllineAmiodarone Increased risk of cardiotoxicity and arrhythmiasAnisindione The macrolide increases anticoagulant effectAprepitant This CYP3A4 inhibitor increases effect and toxicity of aprepitantAstemizole Increased risk of cardiotoxicity and arrhythmiasAtorvastatin The macrolide possibly increases the statin toxicityBretylium Increased risk of cardiotoxicity and arryhthmiasBromocriptine Erythromycin increases serum levels of bromocriptineBuspirone The macrolide increases the effect and toxicity of buspironeCabergoline Erythromycin increases serum levels and toxicity of cabergolineCarbamazepine The macrolide increases the effect of carbamazepineCerivastatin The macrolide possibly increases the statin toxicityCilostazol Erythromycin increases the effect of cilostazolCinacalcet This macrolide increases the serum levels and toxicity of cinacalcetCisapride Increased risk of cardiotoxicity and arrhythmiasCitalopram Possible serotoninergic syndrome with this combinationClozapine Erythromycin increases the effect of clozapineColchicine Severe colchicine toxicity can occurCyclosporine The macrolide increases the effect of cyclosporineDiazepam The macrolide increases the effect of the benzodiazepineDicumarol The macrolide increases anticoagulant effectDigoxin The macrolide increases the effect of digoxin in 10% of patientsDihydroergotamine Possible ergotism and severe ischemia with this combinationDihydroergotoxine Possible ergotism and severe ischemia with this combinationDyphylline The macrolide increases the effect and toxicity of theophyllineDisopyramide Increased risk of cardiotoxicity and arrhythmiasDivalproex sodium Erythromycin increases the effect of valproic acidDocetaxel The agent increases the serum levels and toxicity of docetaxelDofetilide Increased risk of cardiotoxicity and arrhythmiasEletriptan The macrolide increases the effect and toxicity of eletriptanEplerenone This CYP3A4 inhibitor increases the effect and toxicity of eplerenoneErgotamine Possible ergotism and severe ischemia with this combinationErlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinibImatinib The macrolide increases levels of imatinibFelodipine Erythromycin increases the effect of felodipineFluoxetine Possible serotoninergic syndrome with this combinationGefitinib This CYP3A4 inhibitor increases levels/toxicity of gefitinibGrepafloxacin Increased risk of cardiotoxicity and arrhythmiasItraconazole The macrolide increases the effect and toxicity of itraconazoleLevofloxacin Increased risk of cardiotoxicity and arrhythmiasMesoridazine Increased risk of cardiotoxicity and arrhythmiasMethylergonovine Possible ergotism and severe ischemia with this combinationLovastatin The macrolide possibly increases the statin toxicityMethylprednisolone The macrolide increases the effect of corticosteroidMethysergide Possible ergotism and severe ischemia with this combinationMidazolam The macrolide increases the efect of the benzodiazepineMoxifloxacin Increased risk of cardiotoxicity and arrhythmiasOxtriphylline The macrolide increases the effect and toxicity of theophyllinePimozide Increased risk of cardiotoxicity and arrhythmiasQuetiapine This macrolide increases the effect/toxicity of quetiapineQuinidine Increased risk of cardiotoxicity and arrhythmiasQuinidine barbiturate Increased risk of cardiotoxicity and arrhythmiasQuinupristin This combination presents an increased risk of toxicityRanolazine Increased levels of ranolazine - risk of toxicityRepaglinide This macrolide increases effect of repaglinideRifabutin The rifamycin decreases the effect of the macrolideRifampin The rifamycin decreases the effect of the macrolideRitonavir Increased toxicity of both agentsSertraline Possible serotoninergic syndrome with this combinationSibutramine Erythromycin increases the effect and toxicity of sibutramineSildenafil The macrolide increases the effect and toxicity of sildenafilSimvastatin The macrolide possibly increases the statin toxicitySirolimus The macrolide increases sirolimus levelsSotalol Increased risk of cardiotoxicity and arrhythmiasSparfloxacin Increased risk of cardiotoxicity and arrhythmiasTacrolimus Erythromycin increases the effect and toxicity of tacrolimusTerfenadine Increased risk of cardiotoxicity and arrhythmiasTheophylline The macrolide increases the effect and toxicity of theophyllineThioridazine Increased risk of cardiotoxicity and arrhythmiasVerapamil Increased risk of cardiotoxicity and arrhythmiasTriazolam The macrolide increases the effect of the benzodiazepineVardenafil The macrolide increases the effect and toxicity of vardenafilVinblastine Erythromycin increases vinblastine toxicityWarfarin The macrolide increases anticoagulant effectZafirlukast Erythromycin decreases the effect of zafirlukastErgonovine Possible ergotism and severe ischemia with this combinationEverolimus The macrolide increases everolimus levels/toxicityLincomycin Possible antagonism of action with this combinationAcenocoumarol The macrolide increases anticoagulant effect
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Adenosine에 대한 Food Interaction 정보 Avoid caffeine containing foods and drinks. Hydroxocobalamin에 대한 Food Interaction 정보 Not Available
Drug Target	[Drug Target]
Description	Adenosine에 대한 Description 정보 A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [PubChem] Choline에 대한 Description 정보 A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. [PubChem] Cyanocobalamin에 대한 Description 정보 Cyanocobalamin (commonly known as Vitamin B12) is the most chemically complex of all the vitamins. Cyanocobalamin's structure is based on a corrin ring, which, although similar to the porphyrin ring found in heme, chlorophyll, and cytochrome, has two of the pyrrole rings directly bonded. The central metal ion is Co (cobalt). Cyanocobalamin cannot be made by plants or by animals, as the only type of organisms that have the enzymes required for the synthesis of cyanocobalamin are bacteria and archaea. Higher plants do not concentrate cyanocobalamin from the soil and so are a poor source of the substance as compared with animal tissues. Cyanocobalamin is naturally found in foods including meat (especially liver and shellfish), eggs, and milk products. [HMDB] Hydroxocobalamin에 대한 Description 정보 Injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. [PubChem]
Dosage Form	Adenosine에 대한 Dosage_Form 정보 Liquid IntravenousSolution Intravenous Choline에 대한 Dosage_Form 정보 Tablet Oral Cyanocobalamin에 대한 Dosage_Form 정보 Capsule OralLiquid IntramuscularLiquid OralPowder OralSolution IntramuscularTablet OralTablet, extended release Oral Hydroxocobalamin에 대한 Dosage_Form 정보 Liquid IntramuscularSolution Oral
Drug Category	Adenosine에 대한 Drug_Category 정보 AnalgesicsAnti-Arrhythmia AgentsAntiarrhythmic AgentsCardiac drugsVasodilator Agents Choline에 대한 Drug_Category 정보 Dietary supplementLipotropic AgentsMicronutrientNootropic Agents Cyanocobalamin에 대한 Drug_Category 정보 Antianemic AgentsEssential VitaminVitamins (Vitamin B Complex) Hydroxocobalamin에 대한 Drug_Category 정보 Anti-anemic AgentsHematinicsNutritional SupplementVitamin B Complex
Smiles String Canonical	Adenosine에 대한 Smiles_String_canonical 정보 NC1=C2N=CN(C3OC(CO)C(O)C3O)C2=NC=N1 Choline에 대한 Smiles_String_canonical 정보 C[N+](C)(C)CCO Cyanocobalamin에 대한 Smiles_String_canonical 정보 [Co+3].[C-] Hydroxocobalamin에 대한 Smiles_String_canonical 정보 O.[Co++].CC(CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]C1=C(C)C1=NC(=CC3=NC(=C(C)C4=NC2(C)C(C)(CC(N)=O)C4CCC(N)=O)C(C)(CC(N)=O)C3CCC(N)=O)C(C)(C)C1CCC(N)=O)OP([O-])(=O)OC1C(CO)OC(C1O)N1C=NC2=C1C=C(C)C(C)=C2
Smiles String Isomeric	Adenosine에 대한 Smiles_String_isomeric 정보 NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Choline에 대한 Smiles_String_isomeric 정보 C[N+](C)(C)CCO Cyanocobalamin에 대한 Smiles_String_isomeric 정보 [Co+3].[C-] Hydroxocobalamin에 대한 Smiles_String_isomeric 정보 O.[Co++].C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N-]\C1=C(C)/C1=N/C(=C\C3=N\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@]([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2
InChI Identifier	Adenosine에 대한 InChI_Identifier 정보 InChI=1/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1/f/h11H2 Choline에 대한 InChI_Identifier 정보 InChI=1/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1 Cyanocobalamin에 대한 InChI_Identifier 정보 InChI=1/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;-1;+3/p-1/t31?,34-,35-,36-,37+,41+,52?,53?,56?,57+,59-,60+,61+,62+;;/m1../s1/fC62H89N13O14P.CN.Co/h69,85H,63-68H2;;/q-1;2m/b42-23-,54-32-,55-33-;; Hydroxocobalamin에 대한 InChI_Identifier 정보 InChI=1/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+2;/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1/fC62H88N13O14P.Co.H2O/h69H,63-68H2;;/q-2;m;/b42-23-,54-32-,55-33-;;
Chemical IUPAC Name	Adenosine에 대한 Chemical_IUPAC_Name 정보 (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Choline에 대한 Chemical_IUPAC_Name 정보 2-hydroxyethyl-trimethylazanium Cyanocobalamin에 대한 Chemical_IUPAC_Name 정보 Not Available Hydroxocobalamin에 대한 Chemical_IUPAC_Name 정보 Hydroxocobalamin
Drug-Induced Toxicity Related Proteins	ADENOSINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Protein tyrosine phosphatase Drug:adenosine Toxicity:apoptosis. [바로가기] Replated Protein:Adenosine deaminase Drug:adenosine Toxicity:ADA immunodeficiency (SCID). [바로가기] Replated Protein:Mitogen-activated protein kinase 11 Drug:adenosine Toxicity:tactile allodynia. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보